Long‐term effects of dapagliflozin plus saxagliptin versus glimepiride on a background of metformin in patients with type 2 diabetes: Results of a 104‐week extension to a 52‐week randomized, phase 3 study and liver fat MRI substudy

AIM: To report the results of a 104‐week extension to a 52‐week study in which dapagliflozin plus saxagliptin (DAPA+SAXA) improved glycaemic control, liver fat and metabolic variables compared with glimepiride (GLIM) in participants with type 2 diabetes (T2D) receiving background metformin. MATERIAL...

Descripción completa

Detalles Bibliográficos
Autores principales: Frías, Juan P., Maaske, Jill, Suchower, Lisa, Johansson, Lars, Hockings, Paul D., Iqbal, Nayyar, Wilding, John P. H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9293136/
https://www.ncbi.nlm.nih.gov/pubmed/34514692
http://dx.doi.org/10.1111/dom.14548

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9293136/
https://www.ncbi.nlm.nih.gov/pubmed/34514692
http://dx.doi.org/10.1111/dom.14548

Ejemplares similares